Clinical Lymphoma, Myeloma and Leukemia
ISSN: 2152-2650
Datasets associated with articles published in Clinical Lymphoma, Myeloma and Leukemia
Filter Results
8 results
- Data for: A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin followed by Lenalidomide (GROC-Rev)No optimal salvage therapy for relapsed/refractory aggressive histological types of non-Hodgkin lymphoma exists. We explored a combination of single-agent lenalidomide following gemcitabine, rituximab, oxaliplatin combination (“GROC-Rev”) in 33 patients. We observed a response rate of 61% (39% complete response rate) and 3-year overall survival of 47%, superior to previous experience. GROC-Rev is a new salvage regimen with encouraging results.
- Dataset
- Data for: Prevalence and Effect on Survival of Pulmonary Hypertension in MyelofibrosisDataset of myelofibrosis patients with pulmonary artery hypertension.
- Dataset
- Data for: Prevalence and Effect on Survival of Pulmonary Hypertension in MyelofibrosisDataset of myelofibrosis patients who also had echocardiograms performed.
- Dataset
- Data for: Favorable outcomes with tumor burden reduction following the administration of hypomethylating agents before allogeneic hematopoietic cell transplantation in patients with higher-risk myelodysplastic syndromeThis Excel file is the data of the patients we analyzed.
- Dataset
- Data for: Multicenter Phase II Study of Reduced-Dose CHOP Chemotherapy Combined with Rituximab for Elderly Patients with Diffuse Large B-Cell LymphomaWe send the excel file about data to be analyzed for this paper.
- Dataset
- Data for: Bexarotene in Patients with Peripheral T-cell Lymphomas: Results of a Retrospective StudyThis is a retrospective, single-institution, off-label, cohort study of 12 patients with PTCL who were treated with bexarotene monotherapy between 2005 and 2016. Historical information was used with a cutoff date of June 20, 2017.
- Dataset
- Data for: Factors impacting the early death and survival of patients with acute promyelocytic leukemia treated with ATRA-based regimenspatial raw data
- Dataset
- Data for: Marrow Hypocellularity, but Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients with Morphologic Residual DiseaseData set of outcomes based on day 14 bone marrow assessment.
- Dataset